title: Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
abstract: Roughly one-third of individuals living with the human immunodeficiency virus (HIV) are coinfected with the hepatitis C virus (HCV) due to shared routes of transmission. HIV accelerates the progression of HCV disease; thus, coinfected individuals are at high priority for HCV treatment. Several new HCV therapies, called direct-acting antiviral agents (DAAs), are available that achieve cure rates of >90% in many patient populations including individuals with HIV. The primary consideration in treating HCV in HIV-infected persons is the potential for drug interactions. We describe the clinical pharmacology and drug interaction potential of the DAAs, review the interaction data with DAAs and antiretroviral agents, and identify the knowledge gaps in the pharmacologic aspects of treating HCV in individuals with HIV coinfection. This review will focus on DAAs that have received regulatory approval in the United States and Europe and agents in late stages of clinical development.
authors.affiliation: Department of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora.
authors.forename: Christine E
authors.initials: CE
authors.lastname: MacBrayne
authors.affiliation: Department of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora.
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Kiser
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D060085:Coinfection; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D017410:Practice Guidelines as Topic
chemical_list: D000998:Antiviral Agents
keywords: coinfection; direct-acting antivirals; drug interactions; hepatitis C virus; human immunodeficiency virus